Last updated: 2026-09-11 05:17:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Senti Biosciences Holdings, Inc. (SNTI) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.30, with a market capitalization of $9.84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.29 to $2.88. This page covers its latest market performance, valuation, price trends and company information.
$9.84M | |
$0.32 | |
$87.70 | |
$0.29 | |
$0.30 | |
115.31K | |
255.97K | |
-- | |
$2.88 | |
$0.29 | |
-- | |
-- |
Senti Biosciences Holdings, Inc. (SNTI) last closed at $0.30 as of 2026-09-10 23:15:00, unchanged from the previous close of $0.30.
During the latest regular trading session, SNTI traded between $0.29 and $87.70, with a volume of 115.31K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Senti Biosciences Holdings, Inc. (SNTI) moved from $0.38 to $0.30, representing a decline of 20.43% ($0.08).
The stock traded between $0.29 and $0.38 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 129.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.4%
SNTI is currently trading at $0.30, placing it 0.4% of the way from its 52-week low of $0.29 to its 52-week high of $2.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 39 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Senti Biosciences Holdings, Inc. (SNTI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.